IGC Pharma Inc. Common Stock (IGC)

About IGC

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

70

Website

igcpharma.com

Fundamentals

1-day range

$0.2862$0.3031

Market cap

$23.48M

P/E (trailing)

—

P/E (forward)

-3.50

EPS (trailing)

$-0.06

Dividend yield

—

Beta

0.46

Avg. volume

642.3K

Forecasts

2 analyst ratings

IGC Pharma Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• IGC

  IGC Pharma Inc. Common Stock

  $0.3086

  ▼ 6.48%
  Market cap $23.48MP/E —
  $0.24$0.5
• CALC

  CalciMedica Inc. Common Stock

  $0.4644

  ▼ 1.19%
  Market cap $23.14MP/E —
  $0.4606$7.2
• LGVN

  Longeveron Inc. Class A Common Stock

  $6.72

  ▼ 1.47%
  Market cap $23.13MP/E —
  $4.75$12.3
• BRNS

  Barinthus Biotherapeutics plc American Depositary Shares

  $0.7464

  ▲ 2.11%
  Market cap $24.51MP/E —
  $0.512$1.83
• TVRD

  Tvardi Therapeutics Inc. Common Stock

  $1.8

  ▲ 0.00%
  Market cap $25.13MP/E —
  $1.5$43.65
• ACTU

  Actuate Therapeutics Inc. Common stock

  $1.67

  ▼ 1.18%
  Market cap $25.36MP/E —
  $0.9$9.22
• CLRB

  Cellectar Biosciences Inc. Common Stock

  $2.54

  ▲ 0.00%
  Market cap $21.26MP/E —
  $2.2$6.52

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure
  Yahoo · 8/17/2026
• IGC Pharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $265.000K Beat $258.000K Estimate
  Benzinga · 8/17/2026
• IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout
  Yahoo · 8/11/2026

• Claudia Grimaldi · June 30, 2026 · Grant

  2.05M @ $0.27
• Ram Mukunda · June 30, 2026 · Grant

  2.23M @ $0.27
• James P. Moran · April 1, 2026 · Option Exercise

  50.0K
• James P. Moran · April 1, 2026 · Option Exercise

  80.0K
• Claudia Grimaldi · April 1, 2026 · Option Exercise

  138.5K @ $0.26
• Claudia Grimaldi · April 1, 2026 · Option Exercise

  100.0K
• Richard K. Prins · April 1, 2026 · Option Exercise

  70.0K
• Richard K. Prins · April 1, 2026 · Option Exercise

  100.0K
• Ram Mukunda · April 1, 2026 · Option Exercise

  33.3K
• Ram Mukunda · April 1, 2026 · Option Exercise

  16.7K
• Ram Mukunda · April 1, 2026 · Option Exercise

  323.1K @ $0.26
• Ram Mukunda · April 1, 2026 · Option Exercise

  333.3K

Institutional Ownership

March 31, 2026

Total shares held

3.90M

Total value held

$1.02M

Institutional holders

33